193 related articles for article (PubMed ID: 22539748)
1. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
2. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
3. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
5. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
[TBL] [Abstract][Full Text] [Related]
6. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
7. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
Deissler H; Deissler H; Lang S; Lang GE
Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2345-53. PubMed ID: 23760670
[TBL] [Abstract][Full Text] [Related]
9. Internalization of bevacizumab by retinal endothelial cells and its intracellular fate: Evidence for an involvement of the neonatal Fc receptor.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2016 Feb; 143():49-59. PubMed ID: 26481553
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
[TBL] [Abstract][Full Text] [Related]
11. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
Peng S; Adelman RA; Rizzolo LJ
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
[TBL] [Abstract][Full Text] [Related]
12. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
13. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study.
Costa R; Carneiro A; Rocha A; Pirraco A; Falcão M; Vasques L; Soares R
J Cell Biochem; 2009 Dec; 108(6):1410-7. PubMed ID: 19859900
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
[TBL] [Abstract][Full Text] [Related]
17. Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.
Deissler HL; Busch C; Wolf A; Rehak M
Sci Rep; 2022 Jul; 12(1):12493. PubMed ID: 35864147
[TBL] [Abstract][Full Text] [Related]
18. VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A
Deissler HL; Stutzer JN; Lang GK; Grisanti S; Lang GE; Ranjbar M
Exp Eye Res; 2020 May; 194():108004. PubMed ID: 32184103
[TBL] [Abstract][Full Text] [Related]
19. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
[TBL] [Abstract][Full Text] [Related]
20. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A.
Yang J; Wang X; Fuh G; Yu L; Wakshull E; Khosraviani M; Day ES; Demeule B; Liu J; Shire SJ; Ferrara N; Yadav S
Mol Pharm; 2014 Oct; 11(10):3421-30. PubMed ID: 25162961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
